Overview

Left Atrial Appendage CLOSURE in Patients With Atrial Fibrillation Compared to Medical Therapy

Status:
Recruiting
Trial end date:
2025-03-01
Target enrollment:
Participant gender:
Summary
The study goal is to determine the clinical benefit of percutaneous catheter-based left atrial appendage (LAA) closure in patients with non-valvular atrial fibrillation (NVAF) at high risk of stroke (CHA2DS2-VASc Score ≥2) as well as high risk of bleeding as compared to best medical care (including a [non-vitamin K] oral anticoagulant [(N)OAC] when eligible).
Phase:
Phase 4
Details
Lead Sponsor:
Charite University, Berlin, Germany
Collaborators:
Atrial Fibrillation Network
Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK)
Stiftung Institut fuer Herzinfarktforschung
Treatments:
Apixaban
Aspirin
Clopidogrel
Dabigatran
Edoxaban
Phenprocoumon
Rivaroxaban
Warfarin